Outcomes of Ceftriaxone Compared With Cefazolin or Nafcillin/Oxacillin for Outpatient Therapy for Methicillin-Sensitive Staphylococcus aureus Bloodstream Infections: Results From a Large United States Claims Database

被引:1
|
作者
Hamad, Yasir [1 ]
Nickel, Katelin B. [2 ]
Olsen, Margaret A. [2 ,3 ]
George, Ige A. [2 ]
机构
[1] NIH, Crit Care Med Dept, Bethesda, MD USA
[2] Washington Univ, Sch Med St Louis, Dept Med, Div Infect Dis, St Louis, MO 63108 USA
[3] Washington Univ, Sch Med St Louis, Dept Surg, Div Publ Hlth Sci, St Louis, MO USA
来源
OPEN FORUM INFECTIOUS DISEASES | 2024年 / 11卷 / 02期
基金
美国国家卫生研究院;
关键词
bloodstream infection; ceftriaxone; methicillin-sensitive Staphylococcus aureus; MSSA; outpatient parenteral antibiotic therapy; ANTIMICROBIAL THERAPY; PRACTICE GUIDELINES; MANAGEMENT; BACTEREMIA; RESISTANT; ADULTS;
D O I
10.1093/ofid/ofad662
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background Ceftriaxone is a convenient option for methicillin-sensitive Staphylococcus aureus (MSSA) outpatient parenteral antimicrobial therapy (OPAT), but population-based studies for its effectiveness are lacking.Methods In this retrospective cohort, a large insurance claims database was queried from 2010 to 2018 for adults with MSSA bloodstream infection (BSI). Patients discharged on OPAT on cefazolin or oxacillin/nafcillin were compared with ceftriaxone with respect to 90-day hospital readmission with the same infection category and 90-day all-cause readmission using logistic regression models.Results Of 1895 patients with MSSA BSI, 1435 (75.7%) patients received cefazolin, oxacillin, or nafcillin and 460 (24.3%) ceftriaxone. Readmission due to the same infection category occurred in 366 (19.3%), and all-cause readmission occurred in 535 (28.3%) within 90 days. Risk factors significantly associated with readmission with the same infection category were the oldest sampled age group (61-64 years: adjusted odds ratio [aOR], 1.47 [95% confidence interval {CI}, 1.01-2.14]), intensive care unit stay during index admission (aOR, 2.33 [95% CI, 1.81-3.01]), prosthetic joint infection (aOR, 1.96 [95% CI, 1.18-2.23]), central line-associated BSI (aOR, 1.72 [95% CI, 1.33-2.94]), and endocarditis (aOR, 1.63 [95% CI, 1.18-2.23]). Ceftriaxone was not associated with increased risk of readmission with the same infection category (aOR, 0.89 [95% CI, .67-1.18]), or 90-day all-cause readmission (aOR, 0.86 [95% CI, .66-1.10]) when compared with oxacillin/nafcillin/cefazolin.Conclusions In this cohort of MSSA BSI patients discharged on OPAT, there were no differences in outcomes of readmission with the same infection and 90-day all-cause readmission in patients treated with ceftriaxone compared to oxacillin/nafcillin or cefazolin. Patients with complicated BSIs such as endocarditis and epidural abscess were more likely to be prescribed cefazolin or oxacillin/nafcillin.
引用
收藏
页数:7
相关论文
共 13 条
  • [1] Cefazolin versus Nafcillin for Methicillin-Sensitive Staphylococcus aureus Bloodstream Infection in a California Tertiary Medical Center
    Pollett, S.
    Baxi, S. M.
    Rutherford, G. W.
    Doernberg, S. B.
    Bacchetti, P.
    Chambers, H. F.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2016, 60 (08) : 4684 - 4689
  • [2] A comparison of safety and outcomes with cefazolin versus nafcillin for methicillin-susceptible Staphylococcus aureus bloodstream infections
    Miller, Matthew A.
    Fish, Douglas N.
    Barber, Gerard R.
    Barron, Michelle A.
    Goolsby, Tiffany A.
    Moine, Pierre
    Mueller, Scott W.
    JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION, 2020, 53 (02) : 321 - 327
  • [3] Evaluation of the efficacy and safety of outpatient parenteral antimicrobial therapy for infections with methicillin-sensitive Staphylococcus aureus
    Wynn, M
    Dalovisio, JR
    Tice, AD
    Jiang, XZ
    SOUTHERN MEDICAL JOURNAL, 2005, 98 (06) : 590 - 595
  • [4] Outcomes of ceftriaxone use compared to standard of therapy in methicillin susceptible staphylococcal aureus (MSSA) bloodstream infections
    Patel, Ursula C.
    McKissic, Erin L.
    Kasper, Douglas
    Lentino, Joseph R.
    Pachucki, Constance T.
    Lee, Todd
    Lopansri, Bert K.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2014, 36 (06) : 1282 - 1289
  • [5] Outcomes of ceftriaxone use compared to standard of therapy in methicillin susceptible staphylococcal aureus (MSSA) bloodstream infections
    Ursula C. Patel
    Erin L. McKissic
    Douglas Kasper
    Joseph R. Lentino
    Constance T. Pachucki
    Todd Lee
    Bert K. Lopansri
    International Journal of Clinical Pharmacy, 2014, 36 : 1282 - 1289
  • [6] Twice daily cefazolin is effective for treatment of serious methicillin-sensitive Staphylococcus aureus infection in an outpatient parenteral antimicrobial therapy program
    Birrell, Michael T.
    Fuller, Andrew
    THERAPEUTIC ADVANCES IN INFECTIOUS DISEASE, 2019, 6
  • [7] Survival from methicillin-sensitive Staphylococcus aureus bloodstream infections over 20 years: a cohort of 1328 patients
    Benedikt, Wiggli J.
    Reno, Frei
    Reto, Laffer
    Sarah, Tschudin Sutter
    Andreas, Widmer F.
    SWISS MEDICAL WEEKLY, 2017, 147
  • [8] Outcomes of Outpatient Parenteral Antimicrobial Therapy With Ceftriaxone for Methicillin-Susceptible Staphylococcus aureus Bloodstream Infections-A Single-Center Observational Study
    Hamad, Yasir
    Connor, Lee
    Bailey, Thomas C.
    George, Ige A.
    OPEN FORUM INFECTIOUS DISEASES, 2020, 7 (09):
  • [9] Treatment Outcomes with Cefazolin versus Oxacillin for Deep-Seated Methicillin-Susceptible Staphylococcus aureus Bloodstream Infections (vol 59, pg 5232, 2015)
    Rao, Sonia N.
    Rhodes, Nathaniel J.
    Lee, Benjamin J.
    Scheetz, Marc H.
    Hanson, Amy P.
    Segreti, John
    Crank, Christopher W.
    Wang, Sheila K.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (09) : 7159 - 7159
  • [10] Risk factors for community-associated Staphylococcus aureus infections: results from parallel studies including methicillin-resistant and methicillin-sensitive S. aureus compared to uninfected controls
    Como-Sabetti, K. J.
    Harriman, K. H.
    Fridkin, S. K.
    Jawahir, S. L.
    Lynfield, R.
    EPIDEMIOLOGY AND INFECTION, 2011, 139 (03): : 419 - 429